Patents Examined by Daren M. Stephens
  • Patent number: 4110471
    Abstract: N-vinyloxyethyl-.alpha.-methyl-.beta.-phenethylamines represented by the formula ##STR1## wherein R is H, halo or CF.sub.3 and acid addition salts thereof have been found to be useful as alcohol intake suppressing agents.
    Type: Grant
    Filed: September 8, 1976
    Date of Patent: August 29, 1978
    Assignee: Abbott Laboratories
    Inventor: Bruce Wayne Horrom
  • Patent number: 4109014
    Abstract: Novel aromatic guanidine compounds having the formula: ##STR1## wherein: R.sub.1 is hydroxyl, methyl or hydroxymethyl and R.sub.2 is hydrogen or methyl, are found to have biological activity. The guanidine compounds and their salts are shown to be active as vasoconstrictor agents and create useful pharmaceutical preparations when deployed with a pharmaceutically acceptable carrier for administration to a host, e.g., man, requiring vasoconstrictive therapy.
    Type: Grant
    Filed: January 25, 1977
    Date of Patent: August 22, 1978
    Assignee: Armour Pharmaceutical Company
    Inventors: Robert Chung-Huan Liu, John Lawrence Hughes
  • Patent number: 4107295
    Abstract: Antibiotic rubradirin B producible by the controlled fermentation of the known microorganism Streptomyces achromogenes var. rubradiris, NRRL 3061. This antibiotic and its base-addition salts are active against various microorganisms, for example, Staphylococcus aureus, Streptococcus hemolyticus, Sarcina lutea, and Mycobacterium avium. Accordingly, they can be used in various environments to eradicate or control such microorganisms.
    Type: Grant
    Filed: April 15, 1977
    Date of Patent: August 15, 1978
    Assignee: The Upjohn Company
    Inventors: Herman Hoeksema, Fritz Reusser, Donald R. Wait
  • Patent number: 4104370
    Abstract: A method of treating magnesium/potassium depletion which comprises administering pharmaceutical compositions comprising magnesium and potassium compounds, the equivalent weight of the magnesium being between 1 and 3 times the equivalent weight of the potassium, together with a pharmaceutical carrier such that the rate of release of the magnesium and potassium into the digestive system is controlled.
    Type: Grant
    Filed: November 19, 1975
    Date of Patent: August 1, 1978
    Assignee: Smith Kline & French Laboratories Limited
    Inventor: Maurice Bloch
  • Patent number: 4102999
    Abstract: There is provided a process for producing a stable macromomycin (hereinafter often referred to as MCR) powder which comprises adding a stablilizer selected from the group consisting of saccharides, amino acids and salts thereof, organic acid salts, inorganic acid salts and a chelating agent to a solution of macromomycin purified from fermentation broth prior to dehydration as by lyophilization.
    Type: Grant
    Filed: June 1, 1977
    Date of Patent: July 25, 1978
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Hamao Umezawa, Tomio Takeuchi
  • Patent number: 4101675
    Abstract: The invention relates to compounds of the general formula: ##STR1## in which one double bond is present between the carbon atom of the quanidine moiety and one of the adjacent nitrogen atoms andR.sub.0 stands for hydrogen, halogen, hydroxy, alkoxy or alkyl (1 to 6 C),R.sub.1, r.sub.2 for halogen, hydroxy, alkyl (1 to 4 C) or alkoxy (1 to 4 C),R.sub.3, r.sub.3 ', r.sub.3 " for hydrogen or alkyl (1 to 4 C), on the understanding that one of the substituents R.sub.3, R.sub.3 ' or R.sub.3 " is absent because of the presence of the double bond,R.sub.4 for hydrogen, alkyl (1-4 C), hydroxy, alkoxy (1-4 C) or amino optionally substituted with one or two alkyl (1 to 4 C) groups,R.sub.5, r.sub.6 for hydrogen, alkyl (1-6 C), acyl or R.sub.5 + R.sub.6 together represent an alkylidene, cyclic alkylidene or aralkylidene group, as well as the acid addition salts thereof,Provided that, if R.sub.4 stands for methyl and R.sub.0, R.sub.3, R.sub.3 ", R.sub.5 and R.sub.6 for hydrogen, R.sub.1 and R.sub.
    Type: Grant
    Filed: January 29, 1976
    Date of Patent: July 18, 1978
    Assignee: Akzona Incorporated
    Inventor: Harm Jan Panneman
  • Patent number: 4088768
    Abstract: Benzimidazolyl, benzothiazolyl and benzoxazolyl ureas and thioureas are employed as immune regulatory agents, as agents capable of altering the immune response in mammals.
    Type: Grant
    Filed: January 21, 1976
    Date of Patent: May 9, 1978
    Assignee: Eli Lilly and Company
    Inventors: Charles J. Paget, John L. Sands
  • Patent number: 4083976
    Abstract: Novel compounds 10'-[.omega.-N/1,4-diazabicyclo(4,m,0)-alkanyl/-acyl] -phenothiazines having the formula: ##STR1## wherein X = H, Cl, CF.sub.3 ; n = 1, 2, 3; m = 3, 5; and their salts of acidic addition and quaternary salts. The process for producing said compounds comprises reacting .omega. -chloracyl -2-substituted phenothiazines with 1,4-diazabicyclo(4,m,0)-alkanes in an inert solvent medium at a temperature of C followed by isolation of the desired product.Said compounds are pharmacologically active. The most active compound 10'- [.beta.-N-/1,4-diazabicyclo-(4,3,0)-nonanyl/-propyonyl]-2'-chlorophenothia zine of the formula: ##STR2## is an active principle of a medicated compound possessing spasmolytic and coronary-dilatant effect.
    Type: Grant
    Filed: September 24, 1976
    Date of Patent: April 11, 1978
    Inventors: Arkady Mikhailovich Likhosherstov, Liya Semenovna Nazarova, Alexandr Petrovich Skoldinov, Galina Alexandrovna Markova, Natalya Veniaminovna Kaverina
  • Patent number: 4081547
    Abstract: Novel para-polyfluoroisopropyl-anilino-2-oxazolines and thiazolines are provided which exhibit potent antihypertensive properties without significant CNS depression.
    Type: Grant
    Filed: March 19, 1976
    Date of Patent: March 28, 1978
    Assignee: Schering Corporation
    Inventor: Bernard R. Neustadt
  • Patent number: 4080471
    Abstract: A method for inducing increased inotropic effects of the human heart without inducing arrhythmogenic effects, but providing an antiarrhythmogenic effect therein. The method is effected by administering to mammals, including man, a compound of the formula ##STR1## wherein R is selected from the group consisting of hydrogen or ##STR2## wherein R' is selected from the group consisting of straight or branched aliphatic alkyl having 1 to 7 carbon atoms, phenyl, benzyl, and phenylethyl, wherein the phenyl nucleus may be further substituted with alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, alkoxyalkyl having 2 to 8 carbon atoms or halogen, in any position.
    Type: Grant
    Filed: June 25, 1976
    Date of Patent: March 21, 1978
    Assignee: Aktiebolaget Hassle
    Inventors: Enar Ingemar Carlsson, Nils Henry Alfons Persson, Gustav Benny Roger Samuelsson, Kjell Ingvar Leopold Wetterlin
  • Patent number: 4076714
    Abstract: 1-Methyl-4-(2-carboxy-thioxanthen-9-ylidene)-piperidine is disclosed to have pharmaceutical utility as an appetite stimulant and an antihistamine with low antiserotonin and anticholinergic activity. Also disclosed are processes for the preparation of such compound; pharmaceutical compositions comprising such compound; and methods of treatment comprising administering such compound and compositions.
    Type: Grant
    Filed: October 29, 1975
    Date of Patent: February 28, 1978
    Assignee: Merck & Co., Inc.
    Inventors: Paul S. Anderson, David C. Remy
  • Patent number: 4075352
    Abstract: The myocardial function of a human or animal heart to which the oxygen supply has been diminished is improved through parenteral administration of .beta.-hydroxy-.gamma.-trimethylaminobutyric acid or a pharmaceutically acceptable non-toxic salt thereof.
    Type: Grant
    Filed: April 28, 1976
    Date of Patent: February 21, 1978
    Inventor: Stephen L. De Felice
  • Patent number: 4073940
    Abstract: New method for treating cardiac arhythmia by administering to a patient N-(2,5-diethoxy phenyl)-N-(2-diethylamino ethyl)-4-butoxyphenoxy acetamide or a pharmaceutically acceptable acid addition salt thereof.
    Type: Grant
    Filed: October 28, 1976
    Date of Patent: February 14, 1978
    Assignee: Centre Europeen de Recherches Pharmacologiques C.E.R.P.H.A.
    Inventor: Laurent Porte
  • Patent number: 4072758
    Abstract: The invention relates to the use of the compound N-[4-beta-(o-anisamide-ethyl)-benzenesulphonyl]-N'-cyclopentylcarbamide and pharmaceutically acceptable salts thereof as well as compositions therewith plus a pharmaceutical carrier to effect glucoreduction activity, that is lowering of blood sugar levels, with reduced possibility of platelet aggregation and therefore of myocardial infarction.
    Type: Grant
    Filed: February 6, 1976
    Date of Patent: February 7, 1978
    Assignee: J. Uriach y Cia, S.A.
    Inventor: Antonio C. Marin Moga
  • Patent number: 4064273
    Abstract: Hypolipidemic agents of the formula: ##STR1## wherein R is branched lower alkyl,R' is hydrogen or alkyl,X is halo, andn is 2.
    Type: Grant
    Filed: January 16, 1976
    Date of Patent: December 20, 1977
    Assignee: Sandoz, Inc.
    Inventor: Faizulla G. Kathawala
  • Patent number: 4056615
    Abstract: Antifungal and antiprotozoal antibiotic lucknomycin is producible by culturing Streptomyces diastatochromogenes var. Krains in an aqueous nutrient medium under submerged aerobic conditions. Lucknomycin is active against Candida albicans, Candida tropicalis, Candida krusei, Aspergillus niger and more particularly against Trichomonas vaginalis.
    Type: Grant
    Filed: May 24, 1976
    Date of Patent: November 1, 1977
    Assignee: U C B Societe Anonyme
    Inventors: Vinay Chhotalal Vora, Amrut Vithaldas Mody
  • Patent number: 4055643
    Abstract: 5,5,7,7-tetramethyl-3-substituted or unsubstituted-phenylfuro[3,4-e]-as-triazines and corresponding 4-oxides, e.g., 5,7-dihydro-5,5,7,7-tetramethyl-3-phenylfuro[3,4-e]-as-triazine and 5,7-dihydro-5,5,7,7-tetramethyl-3-phenylfuro[3,4-e]-as-triazine-4-oxide, are prepared from 2,2,5,5-tetramethyl-3,4(2H,5H)-furandione-3-hydrazone-4-oximes and are useful as sleep inducers and minor tranquilizers.
    Type: Grant
    Filed: March 10, 1976
    Date of Patent: October 25, 1977
    Assignee: Sandoz, Inc.
    Inventor: Gregory B. Bennett
  • Patent number: 4054662
    Abstract: Compounds of the formula: ##STR1## (wherein R.sub.1 represents a chlorine atom or a methoxy or cyano group;R.sub.2 represents a hydrogen atom or a methyl or hydroxy group;m is 2, 3 or 4; andn is 1 or 2)And their physiologically acceptable acid addition salts have blood pressure reducing properties and may be used in the treatment of patients.
    Type: Grant
    Filed: March 23, 1976
    Date of Patent: October 18, 1977
    Assignee: Beiersdorf Aktiengesellschaft
    Inventors: Rudolf Theodor Petersen, Wolfgang Fleck
  • Patent number: 4048335
    Abstract: 1-(N-isopropyl-N,N-dimethylamino)-3-(1-naphthoxy)propan-2-ol quaternary salts are useful cardiovascular agents as evidenced by their potent and long-acting anti-arrhythmic, anti-fibrillatory and myocardial ischemia-inhibitory activity. They, furthermore, lack the undesirable side-effects, e.g. .beta.-adrenergic receptor blocking and local anesthetic activity, characteristic of related prior art compounds.
    Type: Grant
    Filed: August 19, 1976
    Date of Patent: September 13, 1977
    Assignee: The Regents of the University of Michigan
    Inventor: Benedict R. Lucchesi
  • Patent number: 4046902
    Abstract: Novel thiazole derivatives of the formula ##STR1## wherein R is alkyl of 2 to 12 carbon atoms and R.sub.1 is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and acyl of an organic carboxylic acid of 1 to 12 carbon atoms having hypolipemiant activity with a very prolonged vasodilatatory activity and their preparation.
    Type: Grant
    Filed: February 26, 1976
    Date of Patent: September 6, 1977
    Assignee: Roussel Uclaf
    Inventors: Michel Hardy, Daniel Humbert